A B S T R A C T Cystic fibrosis (CF),
INTRODUCTION
Cystic fibrosis (CF)' is a genetic disease characterized by abnormal exocrine secretion and mucoiliary activity (1, 2) . The pathogenesis of the disease remains unknown at present, but because of the importance of the autonomic nervous system (ANS) in regulating exocrine gland secretion, assessment of adrenergic and cholinergic function has become a major topic of investigation. For example, chronic administration of pharmacologic agents with ANS activity to laboratory animals has been shown to produce exocrine gland function and morphology that closely resembles those seen in CF (3, 4) . Physiologic assessment of the ANS in CF has revealed decreased beta adrenergic, and heightened alpha and cholinergic function (5) (6) (7) (8) . The molecular basis for an ANS abnormality in CF has been best studied for the beta adrenergic system since this pathway, involving the generation of the second messenger cyclic AMP, has been most clearly elucidated (9) . The majority of studies utilizing human tissue have used the skin fibroblast, because this cell produces ciliostatic factor (10) and was thought to be free of drugs and other in vivo effects such as the severity of CF. Unfortunately, data using this model have conflicted with several studies showing enhanced beta adrenergic responses (11, 12) , whereas others report no difference in isoproterenol-induced cyclic AMP generation between CF and control populations (13) . These contradictory observations probably reflect the large number of variables inherent in tissue culture systems.
The human neutrophil offers a number of advantages in this regard. This cell type can be highly purified (>95%) in relatively large numbers (2 x 108/60 ml) without the necessity to establish a cell line in culture. Regulation of neutrophil lysosomal enzyme secretion is controlled by the same neurotransmitters as are found in exocrine tissues. Secretion is inhibited by mediators that increase intracellular cyclic AMP (isoproterenol, histamine, and prostaglandin E1, [PGE1]) and is enhanced by agents that increase cyclic guanosine 5'-monophosphate (GMP) (carbachol) in addition to being calcium dependent as well (14, 15) . Another similarity between these two tissues is the importance of microtubules and microfilaments in macromolecular secretion (16) . Thus, defective ANS regulation of exocrine tissue could be manifest in the CF neutrophil. Using human leukocytes, Davis et al. (17) reported decreased cyclic AMP generation with isoproterenol, but not PGE1 stimulation in CF and in some CF heterozygote (CFH) subjects. The nature of this selective defective response was not elucidated.
We have previously characterized the beta adrenergic receptor in neutrophil sonicates (18 (17) . Whole blood was collected in nonheparinized glass tubes containing a dextran (mol wt 170,000, Sigma Chemical Co., St. Louis, Mo.)-heparin (sodium, preservative-free, Sigma Chemical Co.) mixture in a proportion 5:1), and allowed to settle for 25-30 min at room temperature. The leukocyte-rich fraction was then underlayered with Ficoll-Hypaque and spun at 400 g for 30 min at 20°C (22) , and the resulting pellet washed three times with physiologic saline. The neutrophils in the pellet constituted >95% of the nucleated cells in this fraction. The percentage of band forms (immature neutrophils) was determined by counting 100 nucleated cells stained with Wright stain. CF patients had 11.5±0.87% band forms, whereas control subjects had 3.6±0.5% band forms.
Cyclic AMP assay. For the cyclic AMP assay 5 x 106 neutrophils per tube were preincubated for 5 min at room temperature in incubation buffer (50 mM Tris, pH 7.5, and 8 mM theophylline in physiologic saline) and then exposed to media alone or to hormones (isoproterenol, histamine, and PGE,) at 37°C in a total volume of 100 ,ul for 5 min.
Accumulation of cyclic AMP was terminated by boiling for 5 min and freezing for -30 min. The samples were thawed and assayed for cyclic AMP by the saturation method of Brown et al. (23) . This method permitted quantitative recovery of exogenous [3H]cyclic AMP. The results are expressed as picomoles per 106 cells. The change in neutrophil cyclic AMP after incubation with agonists is expressed as the percentage increase over basal cyclic AMP levels.
DHA binding assay. The binding assay used the same incubation condition as for cyclic AMP.
[3H]DHA (0.1-10 nM) was incubated with 5 x 106 neutrophils per tube containing an incubation volume of 180 ,ul 1 mM ascorbic acid, 0.1 mM phentolamine, and 0.3 mM catechol (which are thought to block nonreceptor binding sites) (24, 25) for 15 min at 37°C, and stopped with 5 ml of Tris, 50 mM HCI, and 10 mM MgCl2 for 30 s. The mixture was then rapidly filtered through a Gelman A-E glass fiber filter presoaked with stop buffer containing 0.1 mM dl propranolol (Gelman Sciences, Inc., Ann Arbor, Mich.). The filters were rapidly washed with 25 ml incubation buffer and counted in a liquid scintillation system. Specific binding represents the total number of DHA counts minus DHA binding in the presence of 0.3 ,IM dl propranolol, and was 50-80% of the total amount bound at all DHA concentrations. We have recently demonstrated the importance of phentolamine (0.1 mM) in reducing nonspecific DHA binding (19) (0) and control subjects' (0) agonist stimulation of neutrophil cyclic AMP. Each agonist was incubated with 5 x 106 cells for 5 min at 37°C after a 5-min preincubation in incubation buffer consisting of 50 mM Tris (pH 7.5) in physiologic saline and 8 mM theophylline (17) . Shown is the percentage of cyclic AMP stimulation above basal values (mean+SEM) for each agonist (10 nM to 0.1 mM). The only consistently significant differences (*) between the two study populations occurred with isoproterenol stimulation (P < 0.025). For isoproterenol there were 37 experiments in the control, 33 in CF group; for histamine and PGEI the number of experiments was 7 and 6 for control and CF groups, respectively. RESULTS Cyclic AMP responses. Fig. 1 illustrates a comparison of isoproterenol, histamine, and PGE,-induced cyclic AMP generation of CF and control subjects' neutrophils, expressed as percentage of stimulation over basal levels. CF patients had significantly less (P < 0.025) beta adrenergic induction of adenylate cyclase than controls at 0.1 uM to 0.1 mM isoproterenol concentrations, as shown by nonpaired Student's t test analysis. There were no consistent differences in cyclic AMP generation induced by either histamine or PGE,, although 10 nM histamine and 0.1 ,uM PGE, were more potent in control subjects (P < 0.025). In Table I the data are expressed as absolute values (pmol/106 cells). CFH are also analyzed. The absolute quantity of cyclic AMP in CF neutrophils was significantly lower for basal (P < 0.025) and for all isoproterenol concentrations used compared with control levels (P < 0.005), whereas CFH were significantly lower than normal controls at isoproterenol concentrations of 1 ,uM to 0.1 mM (P < 0.05). CFH cyclic AMP levels were significantly greater (P < 0.05) than those found in CF subjects for basal and all beta adrenergic hormone responses. Histamine and PGE1
were again not consistently different in CF and normal controls.
DHA binding. A DHA concentration curve comparing control subjects with CF and CFH subjects shows that there is no difference between control and CFH populations, but both groups have significantly more (P < 0.01) DHA binding at all ligand concentrations than the CF group ( Fig. 2A) . A Scatchard plot analysis of the mean data for each group shows that DHA bound to a single class of high affinity sites on the neutrophil membrane (Fig. 2B) . The meantSEM for Bmax and KD calculated from Scatchard analysis of all subjects is shown in Table II . From these data the total number of receptors/neutrophil was determined. These data reveal that both the control with 819.4 +67.2 (mean+SEM) receptors/neutrophil and the CFH group control, CF, and CFH groups, respectively, did not differ significantly (P > 0.05). The severity of CF (Shwachman-Kulczycki score) did not correlate with either the maximum percentage of isoproterenol (0.1 mM)-induced cyclic AMP stimulation or DHA binding at saturation (5 nM DHA concentration). There also appeared to be no correlation l)etween cyclic AMP responsiveness or beta adrenergic receptor binding annd the presence of pancreatic insufficiency, atopy, or the admiinistration of antibiotics or prior bronichodilator therapy (data not shown). The percentage of neuitrophil band formns did not correlate with either the percentage of cyclic AMP stimulation (r = 0.35, P > 0.05), or the absolute quiantity of cyclic AMP generated (r = -0.16, P > 0.05) after maximal isoproterenol (0.1 m M) stimullation (Table III) . Fturthermore, altlhouigh the CF patients were somewhat younger (18.5 +1.3 yr) than control subjects (25.5±1.0 yr), this is not a likely explanation for the differences noted, becauise there was no significant correlation between age and DHA binding or cyclic AMP stimulation in our study popuilation. cyclic AMP generation that is quite specific for the beta adrenergic pathway since neither histaimine nor PGEl-induced adenylate cyclase activation appears abnormal, and since the intrinsic activity of adenylate cyclase itself is normal (26) . In contrast to those investigators who report normal receptor number (27) (20) or that of Davies and Lefkowitz (28) . Details of their methodology are not provided (27) . Furthermore, since our study deals with DHA binding in the intact neutrophil, a direct comparison of our data with those of Davis and Hill (27) may not be appropriate. We must add that although a significant reduction in DHA binding was not found in CFH, it is conceivable that a small (-25%) reduction in receptor sites might be missed because of lack of this degree of sensitivity of our assay system. These findings, suggestive of down regulation of the beta adrenergic receptor associated with the desensitization phenomeienoi, are generally produiced by chronic beta adrenergic stimulation (29) . We have previously demonstrated down regulation in neutrophil sonicates with administration of the beta-2 agonist terbutaline (30) , and others have reported this phenomenon in patients with pheochromocytoma (31) , and after administration of antidepressants (32) (33, 34) . Thus, decreased responsiveness without a chanige in receptor number measured by antagonist ligands, such as DHA, could be due to decreased agonist binding (34) or ain uncoupling of receptor to the enzyme adenylate cyclase (33) . A more profound effect, usually with high agonist concentration or long duration of exposure in some cell types, is a decrease in receptor number (measured by antagonist binding) consistent with diminished adenylate cyclase responsiveness (33) . Desensitization is frequently agonist specific (35) , so that beta adrenergic down regulation is not usually associated with decreased responses to histamine or PGE1.
The beta adrenergic defect in CF could be a conltinuum with the CFH populationi having normiial antagonist binding but abnormal atgonist binding or abnormial receptor-enzyme coupling, so that the result is decreased cyclic AMP generation, whereas the CF patient has a more severe defect consistiing of decreased aintagonist binding and adenylate cyclase activation. If a desensitizationi phenomenon is the basic mechanism behind our observation, we are still without an explanation for this effect. One might consider an intrinsic cellular defect with an increased propensity to desensitize; circulating catecholamine levels that are chronically evaluated, owing to increased synthesis or decreased uptake; or inhibitorv substances produced by the CF cell (11) . Other than for the last nianmed, there is nio evidence for these hypotheses in the literature, and in fact one inivestigation reports decreased norepinephrine levels in CF, although it presents Ino data (13) . Physiologic sttudies in CFH (5) (6) (7) (8) , however, clearly demonstrate ANS imbalance, and this could be associated with disordered catecholaminie metabolism. Study of CFH may hold the key to the primary defect in CF.
Finally, the relationship of the beta adr-energic defect to the disease process deserves coimmiiient. The fact that several investigators (5, 13) , as wvell as ourselves, have fouind evidence of ANS abnormnalities in the asymptomatic CFH subject makes such phenomnena less likely to be important in the pathogenesis of CF. Nevertheless, the CFH population must be fiurther studied to define clearly such beta adrenergic differences between themn and the CF group as receptor binding, coupling 
